The short answer
GHK-Cu is supplied lyophilised and is most stable dry, cold and dark. Being a metal complex rather than a plain peptide, its particular vulnerabilities are pH shifts that can release copper, competing chelators in buffer, and copper's own redox activity in solution.
Key facts
- Supplied as
- Blue lyophilised powder
- Cysteine / methionine
- Neither present
- Specific risk
- Copper loss from the complex
- pH sensitivity
- Binding depends on a deprotonated amide
- Avoid
- Buffers containing competing chelators
- Visual check
- Loss of blue colour indicates a problem
The usual liabilities do not apply
GHK contains no cysteine, so no disulfide chemistry, and no methionine, so none of the +16 Da oxidation that dominates handling guidance for peptides like Semax and MOTS-c. At three residues there is also very little backbone to hydrolyse. As a peptide it is close to the most robust in common use.
But it is not just a peptide
It is a copper complex, and that introduces a category of concern plain peptides do not have. The copper is bound reversibly (that reversibility is central to the proposed carrier mechanism), which means conditions that shift the equilibrium can release it. A GHK-Cu preparation that has lost its copper is free GHK, which is a different compound with a different mass.
Research material referenced
GHK-Cu 100mg, third-party HPLC tested
What shifts the equilibrium
Three things in ordinary use. Low pH, because binding requires a deprotonated backbone amide and acid pushes that proton back on. Competing chelators: EDTA is the obvious one, and it is present in more buffers than people expect. And very high dilution, which favours dissociation as it does for any reversible complex.
Copper redox chemistry
Free copper ions catalyse formation of reactive oxygen species, which is why biology keeps copper bound to carrier proteins rather than loose. Copper released from a degraded complex is not inert, and in a solution containing other biomolecules it can promote oxidative damage to them. This is a reason to care about complex integrity beyond simply knowing what you have.
The colour tells you
The blue of the complex comes from copper(II) in its coordination environment. Fading, or a solution that never developed the expected colour on reconstitution, indicates the copper is not bound as intended. No other research peptide offers a diagnostic this direct, and it costs nothing to look.
Practical handling
Store lyophilised, cold, dry and dark. Reconstitute with diluent introduced gently down the vial wall and swirl rather than shake, because foaming creates the air-liquid interface at which peptides denature. Prefer a diluent without chelating agents. Aliquot to avoid repeated freeze-thaw cycling. Bacteriostatic water at pH 5.7 is mildly acidic, which is useful to know for a complex whose stability is pH-dependent.
Frequently asked questions
Can GHK-Cu lose its copper?
Yes. Binding is reversible, and low pH, competing chelators such as EDTA, or high dilution can shift the equilibrium toward the free peptide.
How would I know?
Loss of the blue colour. Copper(II) coordination is what produces it, and fading indicates the copper is no longer bound as intended.
Does GHK-Cu need a reducing agent?
No, there is no cysteine. Reducing agents would in fact be inadvisable given copper's redox chemistry.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · GHK-Cu copper complex (CID 71587328)pubchem.ncbi.nlm.nih.gov
- PubMedPickart L, GHK-Cu in prevention of oxidative stress. Oxid Med Cell Longev 2012 (PMID 22666519)pubmed.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubMedPickart L & Margolina A, GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015 (PMID 26236730)pubmed.ncbi.nlm.nih.gov
- PubMedPickart L et al., The Effect of the Human Peptide GHK on Gene Expression. Brain Sci 2017 (PMID 28212278)pubmed.ncbi.nlm.nih.gov
- PubMedPickart L, The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008 (PMID 18644225)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Glycyl-L-histidyl-L-lysine (CID 73587)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More GHK-Cu (Copper Peptide) articles
- Copper Tripeptide-1: The Cosmetic Ingredient NameCopper tripeptide-1 is the INCI name for GHK-Cu used on cosmetic labels. Same molecule, different regulatory framework - and that difference matters.
- Research GHK-Cu and Cosmetic Copper Peptides ComparedCosmetic copper peptide products contain copper tripeptide-1 under cosmetics regulation. Research material is unformulated and sits under no such framework.
- Copper Peptides: What the Term CoversCopper peptide describes any peptide that binds copper, not one compound. What unites the class, and why GHK-Cu is the most studied member.
- Loren Pickart and the GHK Research ProgrammePickart isolated GHK in 1973 and has authored much of its literature since. What that concentration of authorship means for reading the evidence.
- GHK-Cu in Skin ResearchMost GHK-Cu skin work is in vitro or in animal models. What the studies measured, what the model systems can support, and where the claims outrun them.